Velocardiofacial Syndrome (VCFS) – A Comprehensive Medical Guide

Overview

Velocardiofacial syndrome (VCFS), also called 22q11.2 deletion syndrome, DiGeorge syndrome, or Shprintzen syndrome, is a genetic disorder caused by a small missing piece of chromosome 22 (the q11.2 region). The deletion affects multiple organ systems, leading to a wide spectrum of clinical features that can range from mild learning difficulties to severe cardiac malformations.

Who it affects: The condition occurs in both males and females of all ethnic backgrounds. It is inherited in an autosomal dominant pattern, meaning a single copy of the deleted chromosome is enough to cause the disorder. Approximately 90 % of cases are de‑novo (new mutations), while the remaining 10 % are inherited from an affected parent.

Prevalence: VCFS is one of the most common microdeletion syndromes, affecting roughly 1 in 2,000–4,000 live births worldwide (CDC; Mayo Clinic). Because many individuals have subtle signs, the true prevalence may be higher.

Symptoms

Symptoms vary widely, even among family members with the same deletion. Below is a comprehensive list, grouped by system.

Facial features

• Small, narrow nose with a flat nasal bridge – often gives a “bulbous” appearance.
• Small mouth, long philtrum, and thin upper lip.
• Low-set, slightly rotated ears.
• Micrognathia (small jaw) – may affect speech and chewing.

Cardiac anomalies

• Conotruncal defects – most common: Tetralogy of Fallot, truncus arteriosus, interrupted aortic arch, and ventricular septal defect (VSD).
• Less common: Atrial septal defect (ASD), patent ductus arteriosus (PDA).

Respiratory & Immunologic

• Recurrent sinus and ear infections due to abnormal thymic development.
• Chronic cough, wheezing, and obstructive sleep apnea (often from enlarged tonsils/adenoids).
• Hypocalcemia (low calcium) caused by under‑active parathyroid glands – can lead to muscle cramps or seizures.

Growth & Development

• Failure to thrive in infancy; short stature in adulthood.
• Feeding difficulties, especially with solid foods.
• Delayed milestones – sitting, crawling, walking may be 2–6 months later than peers.

Neurocognitive & Psychiatric

• Learning disabilities (average IQ 70–85), especially with mathematics and abstract reasoning.
• Language-based disorders – dyslexia, expressive language delay.
• Attention‑deficit/hyperactivity disorder (ADHD) in 30–50 % of patients.
• Increased risk of autism spectrum disorder (ASD) – 10–20 %.
• Higher prevalence of anxiety, mood disorders, and schizophrenia (approximately 25 % develop psychotic illness in adulthood).

Ear, Nose & Throat

• Hearing loss (conductive, sensorineural, or mixed) – often due to chronic otitis media or structural abnormalities.
• Velopharyngeal insufficiency leading to hypernasal speech.
• Palatal abnormalities – cleft palate (complete or submucosal) in 10–15 %.

Other possible features

• Kidney abnormalities (e.g., unilateral renal agenesis, hydronephrosis).
• Immune deficiency – low T‑cell count, increased susceptibility to viral infections.
• Endocrine problems – thyroid disease, diabetes mellitus type 2 later in life.
• Skeletal anomalies – scoliosis, clinodactyly of the fifth finger.

Causes and Risk Factors

VCFS is caused by a hemizygous deletion of a ~3‑megabase segment on chromosome 22q11.2 that includes more than 30 genes. The most critical gene is TBX1, which plays a key role in the development of the heart, thymus, and palate.

Key risk factors:

• Parental carrier status: About 10 % of cases are inherited; an affected parent has a 50 % chance of passing the deletion to each child.
• Advanced maternal age: Slightly higher odds of de‑novo deletions, similar to other chromosomal anomalies.
• Family history of related cardiac, facial, or neuropsychiatric disorders: May raise suspicion.

There are no lifestyle or environmental exposures known to cause the deletion; it is a random genetic event during the formation of egg or sperm cells.

Diagnosis

Because VCFS presents with a broad spectrum, diagnosis often begins with a clinical suspicion based on the combination of facial features, cardiac defects, and developmental issues.

Clinical evaluation

• Detailed medical and family history.
• Physical examination focusing on characteristic facies, palate, heart sounds, and growth parameters.

Genetic testing – the gold standard

1. Fluorescence in situ hybridization (FISH): Detects the 22q11.2 deletion in ~95 % of cases. Quick (24–48 h) and widely available.
2. Chromosomal microarray (CMA): Higher resolution than FISH; can identify atypical breakpoints and additional copy‑number changes.
3. Multiplex ligation‑dependent probe amplification (MLPA): Useful when CMA is unavailable.
4. Whole‑genome sequencing (WGS): Reserved for research or complex cases where microarray is negative but suspicion remains high.

Additional investigations

• Echocardiogram: To identify structural heart defects.
• Calcium and parathyroid hormone (PTH) levels: Detect hypocalcemia.
• Immunologic work‑up: T‑cell counts, vaccine response testing.
• Audiology assessment: Baseline and periodic hearing tests.
• Neuropsychological testing: Baseline cognitive profile and learning needs.
• Renal ultrasound: Screen for congenital kidney anomalies.

Treatment Options

Management is multidisciplinary; there is no cure, but most symptoms are treatable.

Cardiac care

• Medical therapy (e.g., beta‑blockers, diuretics) for heart failure or arrhythmias.
• Surgical repair of conotruncal defects – typically performed in the first year of life.
• Regular follow‑up with a pediatric cardiologist; many adults require lifelong surveillance.

Calcium & endocrine management

• Acute hypocalcemia: Intravenous calcium gluconate.
• Chronic management: Oral calcium carbonate or citrate plus active vitamin D (calcitriol).
• Monitor serum calcium, magnesium, and PTH every 6–12 months.

Immunologic support

• Vaccinations per routine schedule; consider pneumococcal and influenza boosters.
• Prophylactic antibiotics for severe T‑cell deficiency (rare).
• Consultation with an immunologist when T‑cell counts are <500 cells/µL.

Speech, feeding, and ENT

• Feeding therapy for infants with oral motor delays.
• Palatal surgery (e.g., Furlow palatoplasty) for cleft or submucosal palate.
• Speech‑language pathology to address velopharyngeal insufficiency and articulation.
• Adenotonsillectomy for obstructive sleep apnea; consider continuous positive airway pressure (CPAP) if surgery is not sufficient.

Neurocognitive & psychiatric care

• Early intervention programs (IDEA) for developmental delays.
• Individualized Education Programs (IEP) in school.
• Medication for ADHD (stimulants or non‑stimulants) and anxiety (SSRIs).
• Regular psychiatric evaluation, especially during adolescence, to screen for emerging psychosis.

Orthopedic & other specialty care

• Physical therapy for low muscle tone and coordination.
• Scoliosis screening; brace or surgery if curvature progresses.
• Renal follow‑up if structural anomalies are present.

Lifestyle & supportive measures

• Balanced diet rich in calcium and vitamin D.
• Regular exercise to maintain cardiovascular health and bone density.
• Stress‑reduction techniques – mindfulness, counseling, or support groups.

Living with Velocardiofacial Syndrome

Successful management focuses on early detection, consistent follow‑up, and a supportive environment.

Practical daily‑management tips

1. Create a health record binder: Include genetic test results, cardiac reports, calcium levels, vaccination history, and contact information for each specialist.
2. Medication organization: Use a weekly pillbox; set alarms for calcium/Vit‑D supplements.
3. School collaboration: Work with teachers and school counselors to implement accommodations (extra time on tests, preferential seating, speech‑language support).
4. Routine health checks: Schedule annual cardiac echo, calcium panel, audiology exam, and neuropsychological review.
5. Nutrition: Incorporate calcium‑rich foods (dairy, fortified plant milks, leafy greens) and limit caffeine, which can impair calcium absorption.
6. Social skills development: Participation in group activities or clubs can reduce isolation and improve self‑esteem.
7. Support networks: Join organizations such as the 22q11.2 Deletion Syndrome Support Group for peer advice.

Transition to adult care

Adolescents should gradually shift from pediatric to adult providers. A coordinated transition clinic (cardiology, genetics, psychiatry, primary care) reduces gaps in care and improves health outcomes (Cleveland Clinic).

Prevention

Because VCFS is a genetic microdeletion, primary prevention (avoiding the condition) is not possible. However, families can take steps to reduce the risk of complications:

• Genetic counseling before or during pregnancy – carrier testing if a parent is known to have the deletion.
• Maternal prenatal care: high‑resolution ultrasound can sometimes detect major cardiac or cleft palate anomalies, prompting early post‑natal evaluation.
• Early newborn screening for hypocalcemia in infants with dysmorphic features.
• Vaccination adherence to prevent infections that could exacerbate immune deficiency.

Complications

If not identified and managed promptly, VCFS can lead to serious health problems:

• Life‑threatening cardiac defects – untreated Tetralogy of Fallot or truncus arteriosus may cause heart failure.
• Severe hypocalcemia – can trigger seizures, tetany, or cardiac arrhythmias.
• Recurrent otitis media – may cause permanent hearing loss.
• Psychiatric illness – early‑onset schizophrenia or severe mood disorders increase risk of self‑harm.
• Chronic kidney disease – from congenital anomalies that go undetected.
• Immunodeficiency‑related infections – especially in early childhood when thymic tissue is under‑developed.

When to Seek Emergency Care

References

• Mayo Clinic. “22q11.2 deletion syndrome (DiGeorge syndrome).” https://www.mayoclinic.org
• Centers for Disease Control and Prevention. “22q11.2 Deletion Syndrome.” https://www.cdc.gov
• National Institutes of Health, Genetics Home Reference. “22q11.2 deletion syndrome.” https://ghr.nlm.nih.gov
• World Health Organization. “Congenital heart disease.” https://www.who.int
• Cleveland Clinic. “Transition of Care for Adolescents with Complex Genetic Disorders.” https://my.clevelandclinic.org
• Shprintzen RJ, et al. “22q11.2 deletion syndrome.” Nature Reviews Disease Primers. 2020;6:80. doi:10.1038/s41572-020-00236‑z.